China biotech will slow as it nears R&D frontier, Pfizer’s Baum predicts
China’s rapid advance in biotech will slow as companies there begin to experiment on the cutting edge of R&D, according to Pfizer’s Andrew Baum, who expects the risks of biology and drug development will create ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- The China Debate: Biotech deserves a deeper discussion endpoints.news
